Trial · NCT01190930
Results by group55
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 55
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization | B-ALL Average Risk: MTX 20 mg/m^2/Week Starting Dose | 95.05 | 95% Confidence Interval 93.27 to 96.83 | percent probability | |
| Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization | B-ALL Average Risk: MTX 40 mg/m^2/Week Starting Dose | 94.17 | 95% Confidence Interval 92.23 to 96.11 | percent probability | |
| DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization | B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks | 94.10 | 95% Confidence Interval 92.16 to 96.04 | percent probability | |
| DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization | B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks | 95.13 | 95% Confidence Interval 93.35 to 96.91 | percent probability | |
| DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens | B-ALL Low Risk Arm I (LR-M) | 98.75 | 95% Confidence Interval 97.14 to 100.00 | percent probability | |
| DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens | B-ALL Low Risk Arm II (LR-C) | 98.50 | 95% Confidence Interval 96.75 to 100.00 | percent probability | |
| DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care | Standard Risk With Down Syndrome | 89.77 | 95% Confidence Interval 83.60 to 95.94 | percent probability | |
| Sample Collection of Central Path Review Slides in B-LLy Patients | B-LLy | 89.7 | 95% Confidence Interval 80.2 to 99.3 | percentage of patients | |
| Event Free Survival (EFS) for B-LLy Patients | B-LLy | 94.54 | 95% Confidence Interval 78.17 to 100.00 | percent probability | |
| Overall Survival (OS) for B-LLy Patients | B-LLy | 93.97 | 95% Confidence Interval 76.88 to 100.00 | percent probability | |
| Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional | B-ALL Average Risk | -1.21 | Standard Deviation 1.14 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional | B-ALL Average Risk | -0.86 | Standard Deviation 1.10 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional | B-ALL Average Risk | -0.84 | Standard Deviation 1.11 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional | B-ALL Average Risk | -0.74 | Standard Deviation 1.10 | Z-Score | |
| Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional | B-ALL Average Risk | -0.62 | Standard Deviation 1.26 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical | B-ALL Average Risk | -1.44 | Standard Deviation 1.10 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical | B-ALL Average Risk | -0.59 | Standard Deviation 1.02 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical | B-ALL Average Risk | -0.63 | Standard Deviation 1.06 | Z-Score | |
| Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical | B-ALL Average Risk | -0.66 | Standard Deviation 1.15 | Z-Score | |
| Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical | B-ALL Average Risk | -0.67 | Standard Deviation 1.23 | Z-Score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01190930/results